Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

time. Investors interested in listening to the live webcast should log on before the presentation begins to download any software required. The archive of the presentation will be available for several days following the event.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is awaiting authorization to begin the delivery of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical development pipeline.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  Sanomedics, Inc. (OTC: SIMH, ... company focused on developing, manufacturing, and acquiring cutting-edge technology, ... Thermomedics, Inc., will be exhibiting at booth # 709 ... Conference (NAPNAP) taking place on March 11-13, 2015 ... The 36 th ...
(Date:3/5/2015)... March 5, 2015  Relmada Therapeutics, Inc. (OTCQB: ... the treatment of chronic pain, today announced the ... advisory roles. The panel of experts will provide ... efforts to advance the company pipeline of novel ... expertise in a range of areas including opioid ...
(Date:3/5/2015)... , March 5, 2015 LUNGevity ... the Food and Drug Administration,s (FDA) approval of ... Opdivo and other immunotherapy treatments add another critical ... harnessing the power of a patient,s own immune ... has been approved specifically for patients with squamous ...
Breaking Medicine Technology:Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3
... 7, 2011 Johnson & Johnson (NYSE: JNJ ... agreement to become a global sponsor of the 2014 FIFA ... Cup™ Sponsor. With this sponsorship, Johnson & Johnson ... ability to activate across their Consumer, Medical Devices & Diagnostics ...
... Health IT Services Group (HITSG) announced today that its ... this month, continuing its growth as the largest Electronic ... by nephrologists for nephrologists, the Acumen nEHR enables all ... patient information, so that regardless of who treats the ...
Cached Medicine Technology:Johnson & Johnson Announces Global Sponsorship of the 2014 FIFA World Cup Brazilâ„¢ 2Acumen nEHR Surpasses 1,000 Nephrology Providers 2
(Date:3/5/2015)... This week, 60 Minutes ... laminate flooring products, initiating widespread concern from homeowners. ... materials made primarily from bamboo, stands behind their ... flooring products for volatile organic compounds (VOCs) through ... (BMH). Results from formaldehyde emissions testing show ...
(Date:3/5/2015)... 05, 2015 Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ... heart attacks, strokes and other serious cardiovascular events due ... to move forward in the federal multidistrict litigation now ... According to a Case Management Order issued on March ... use of master pleadings in the proceeding. Among other ...
(Date:3/5/2015)... The Maricopa Community Colleges add $7.3 ... economy each year, according to a research report released ... Maricopa County Community College District, summarizes economic impact and ... year 2013-2014. , The analysis was conducted by ... that specializes in providing economic impact studies and labor ...
(Date:3/5/2015)... TCS Healthcare Technologies (TCS), a leading provider of ... arena, is pleased to announce a webinar focusing on ... (ACUITY) version 7.20. The session will focus on the ... automation. , The webinar, scheduled for March 18, 2015 ... Frater, RN, BSN, Director of Partner Development at TCS. ...
(Date:3/5/2015)... 2015 Califia Farms , the ... natural products coffee drinks category[1], today unveils its new ... in Anaheim, Calif. Concentrated Cold Brew (CCB) is ... which democratizes the next wave of the coffee-taste evolution ... to become their own baristas. , Califia Farms ...
Breaking Medicine News(10 mins):Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4
... Palmer Hospital, are hosting Grossology, an interactive exhibit designed to teach ... ... (PRWEB) January 29, 2009 -- The Orlando Science Center and presenting ... Science of the Human Body, a colorful, hands-on exhibit that uses ...
... funding research for the genetic disorder cystinosis, unveils new communication ... ... Forest, IL (PRWEB) January 29, 2009 -- The Cystinosis Research ... for the rare genetic disorder cystinosis, has launched a new ...
... CHARENTON-LE-PONT, France, January 29 , - A New ... 9.7% Excluding the Currency Effect, - Higher Earnings ... in ophthalmic optics, today,announced consolidated revenue of EUR3,074.5 million for the ... previous,year. Excluding the currency effect, growth for the year was a ...
... OH, January 29, 2009 -- Recent studies have suggested ... among children born very prematurely. The early symptoms ... to preterm births, such as cerebral palsy, which can ... Because of this, researchers have begun to explore ...
... "super bugs" because our antibiotic arsenal has run dry, leaving ... infectious disease researchers at The University of Texas Medical School ... The New England Journal of Medicine , Barbara E. Murray, ... and future response to preventing and treating "super bugs." , ...
... Dramatic New Study Presented in Congressional Briefing TodayOAKLAND, ... which Congress prepared to vote on the Obama ... nation,s largest organization of registered nurses said expanding ... of the most effective economic recovery programs - ...
Cached Medicine News:Health News:Grossology Exhibit Captivates Kids at The Orlando Science Center 2Health News:Grossology Exhibit Captivates Kids at The Orlando Science Center 3Health News:Cystinosis Research Network Unveils New Communication Strategy and Website 2Health News:Essilor : 2008 Revenue 2Health News:Essilor : 2008 Revenue 3Health News:Essilor : 2008 Revenue 4Health News:Essilor : 2008 Revenue 5Health News:Essilor : 2008 Revenue 6Health News:New study explores the relationship between preterm birth and autism spectrum disorder 2Health News:Call to action: Running out of options to fight ever-changing 'super bugs' 2Health News:Call to action: Running out of options to fight ever-changing 'super bugs' 3Health News:Nurses to Congress: Expanding Medicare Could Reverse Job Losses, and Repair Our Broken Healthcare System and Safety Net 2Health News:Nurses to Congress: Expanding Medicare Could Reverse Job Losses, and Repair Our Broken Healthcare System and Safety Net 3
Intended for the quantitative determination of total protein in serum. Reaction: endpoint. Wavelength: 540 nm. Linearity: 12 g/dL (120 g/L). Ready to use liquid reagent....
For the determination of urea nitrogen in human serum....
... Intended for the quantitative determination ... Reaction: kinetic, lag phase of ... by linear phase of at ... nm. Linearity: 120 mg/dL (42.8 ...
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Medicine Products: